Turn on, tune in: New York biotech scores $15M+ in chemo­ge­net­ics bet

Typ­i­cal­ly, once a bi­o­log­i­cal tar­get has been iden­ti­fied, sci­en­tists work on de­vel­op­ing mol­e­cules fo­cused on that tar­get. But in an emerg­ing field called chemo­ge­net­ics, re­searchers start with a small mol­e­cule and then de­sign a tar­get for it.

Bank­ing on its chemo­ge­net­ics tech­nol­o­gy to ad­dress CNS dis­or­ders, New York-based Red­pin Ther­a­peu­tics has se­cured a $15.5 mil­lion in­jec­tion, as it shep­herds its two pre­clin­i­cal pro­grams — for chron­ic pain and re­frac­to­ry epilep­sy — in­to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.